INC Research and Debiopharm Group(TM) Announce Strategic Partnership
LAUSANNE, Switzerland and RALEIGH, North Carolina, July 26, 2011 /PRNewswire/ --
INC Research, LLC, a therapeutically focused contract research organisation (CRO) with a trusted process for delivering reliable results, and Debiopharm Group™ ("Debiopharm"), a Swiss-based global biopharmaceutical group with a focus on drug development and companion diagnostics, today announced a strategic partnership. Under the terms of the agreement, Debiopharm will entrust INC Research with the management of a clinical study linked to an important project in Debiopharm's pipeline. Both parties have furthermore agreed on a framework partnership pertaining to future clinical studies to be conducted by INC Research for Debiopharm.
"Debiopharm's reputation and success in establishing partnerships is aligned very closely with our vision of creating strategic relationships that improve the speed, efficiency, and quality of drug development," said Kelvin Logan, Ph.D., president INC Research Europe and Asia Pacific, who added "we are pleased to offer our therapeutic expertise along with our experience in conducting trials globally to support Debiopharm's drug development efforts in bringing innovative medicines to market more quickly and efficiently."
"It is through our successful partnerships that we have been able to build and maintain a truly leading global biopharmaceutical development group, while supporting and conducting several clinical development programmes on a continuous basis," said Dr Rolland-Yves Mauvernay, President and Founder of Debiopharm. "This partnership with INC Research will significantly help us in our endeavours to conduct our clinical development programmes efficiently, which in turn will enable us to continue to fuel our pipeline with important new medicines."
INC Research's clinical delivery alliance structures can include complete management of a compound or therapeutic area; management of a specific function or set of critical processes; sharing in the risk and reward of a compound's performance; or acting as the sole source development partner for a customer. The company's proven experience with process-driven clinical research methods and its popular metrics-based Trusted Process® provides the foundation for successful strategic alliances.
About Debiopharm Group
Debiopharm Group™ (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses, develops and/or co-develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III as well as earlier stage candidates. It develops its products for global registration and maximum commercial potential. The products are out-licensed to pharmaceutical partners for sales and marketing. Debiopharm is also active in the field of companion diagnostics with a view to progressing in the area of personalised medicine. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs. For more information on Debiopharm Group™, please visit: http://www.debiopharm.com.
About INC Research, LLC
INC Research is a therapeutically focused contract research organisation with a high performance reputation for conducting global clinical development programmes (http://www.incresearch.com/Global/Global-CRO.aspx) of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV (http://www.incresearch.com/Services/Contract-Research-Organization.aspx) programmes in therapeutic areas of specialty (http://www.incresearch.com/Therapeutic/Clinical-Trials-Services.aspx), and in innovative pediatric and women's health trials. The company's Trusted Process® (http://www.incresearch.com/TheTrustedProcess/Clinical-Trials-Outsourcing.aspx) methodology and therapeutic foresight leads customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, NC. For more information please visit http://www.incresearch.com or follow us at http://twitter.com/#!/inc_research.
Maurice Wagner, Ph.D.
Director Corporate Affairs & Communication
Additional Media Contacts
In New York
Russo Partners, LLC
Martina Schwarzkopf, Ph.D.
SOURCE The Debiopharm Group
More by this Source
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.